A. E. van Leeuwen-Stok

发表

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

V. Tjan-Heijnen, F. Erdkamp, B. Ramaekers, 2022, Acta oncologica.

Radiotoxic effect and dosimetry of 67GA in multicellular spheroids as compared to single cells of the lymphoma cell line U715.

G. Teule, G. Schuurhuis, P. Huijgens, 1996, International journal of radiation oncology, biology, physics.

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

H. Putter, E. Rutgers, E. Rutgers, 2018, Journal of the National Cancer Institute.

Gallium 67 in the human lymphoid cell line U-715: uptake, cytotoxicity and intracellular localization.

G. Teule, G. Schuurhuis, P. Huijgens, 1993, International journal of radiation biology.

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial

S. Sleijfer, A. Jager, S. Linn, 2016, Cancer.

Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

H. Verkooijen, I. Nagtegaal, L. Boersma, 2021, Journal of Hematology & Oncology.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

A. van Oudenaarden, H. Horlings, L. Kester, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

M. Welters, J. Nortier, V. Longo, 2020, Nature Communications.

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

M. Welters, J. Nortier, V. Longo, 2020, Nature Communications.

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.

E. Rutgers, J. Wesseling, R. Pijnappel, 2015, European journal of cancer.

Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)

P. Nederlof, S. Linn, M. Kok, 2021, Breast Care.

Effect of modulation of the transferrin receptor on gallium-67 uptake and cytotoxicity in lymphoma cell lines.

G. Teule, G. Schuurhuis, P. Huijgens, 1996, British Journal of Cancer.

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).

H. Putter, J. Nortier, J. Kroep, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Elastosis in ERα-positive male breast cancer

P. V. van Diest, C. V. van Deurzen, P. Diest, 2020, Virchows Archiv.

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study.

C. Seynaeve, J. Nortier, B. V. van Munster, 2013, Breast.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

A. Oudenaarden, A. van Oudenaarden, H. Horlings, 2021, Clinical Cancer Research.

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

S. Linn, M. Kok, J. Wesseling, 2018, European journal of cancer.

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

H. Putter, H. Pijl, V. Smit, 2015, Breast Cancer Research and Treatment.

Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.

H Putter, H. Putter, J. Nortier, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Breast.

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).

H. Putter, J. Nortier, V. Smit, 2016, Breast.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014 .

Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04).

H. Horlings, L. Wessels, M. Kok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.